Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes (PRIME)

1 de noviembre de 2026 actualizado por: Maja Guberina, University Hospital, Essen

High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes; PRIME: P: Precision R: Radiosurgery I: Intervention M: Minimal Invasive Surgical Approach E: EYESIGHT

High-precision radiosurgery followed by minimally invasive surgical approach in patients with high-prominence uveal melanomas: modern radiation techniques and outcomes. Evaluation of outcome regarding multiparametric parameters and co-factors

Descripción general del estudio

Descripción detallada

The aim here is to prospectively evaluate modern technical standards. The aim of this study is to assess the influence of the updated basic diagnostics and high-resolution diagnostics for radiation planning and the new technical therapy standards (therapy options in application: volume modulated rapid arc technique (VMAT) / online arc technique (VMAT) / online onboard image-guidance (IGRT), by means of the newly established Clinic for Radiation Therapy 2019-2021) depending on known prognostic parameters for quality assurance of the long-term outcome (overall survival, local tumor control). This will lay the basis for standardizing treatment parameters as far as possible, but also to introduce improvements in the treatment of future patients.

Scientific background (state of research (with literature references) and

Derivation of the research question (rationale)):

The eye can be affected by several neoplastic processes, which can lead either primarily or secondary to systemic metastasis. The most common primary tumors of the eye include conjunctival melanoma and uveal melanoma. Metastases from systemic malignant diseases, particularly of the breast and lungs, can also affect the eye.

A combination of ophthalmologic examination, MRI and additional tests and cytologic/histopathologic evaluation leads to an accurate diagnosis.

Depending on the tumor manifestation, treatment consists of a multimodal concept. In the case of uveal melanomas and the aim of preserving the globe and and visual acuity preservation, radiotherapy is one of the most important treatment modalities that can be applied.

In the last 20 years, radiotherapy has developed rapidly away from two-dimensional modulated, three-dimensional techniques. But here too the high level of technical diversity in radiotherapy and ever newer technical innovations, there is a broad spectrum of radiotherapy. Standard therapy can be performed using modern devices, the high-precision stereotactic linear accelerators (irradiation devices), can be safely further optimized. This is to be tested in the Department of Radiotherapy.

Tipo de estudio

De observación

Inscripción (Estimado)

250

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Essen, Alemania
        • Reclutamiento
        • University Hospital Essen
        • Contacto:
      • Essen, Alemania, 45147
        • Reclutamiento
        • Maja Guberina
        • Contacto:
    • Germany / NRW
      • Essen, Germany / NRW, Alemania, 45147
        • Reclutamiento
        • Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West
        • Contacto:
          • Maja Guberina, PD Dr. med. (MD), specialist
          • Número de teléfono: +492017232321
          • Correo electrónico: maja.guberina@uk-essen.de
        • Contacto:
          • Ina Grübel
        • Investigador principal:
          • Maja Guberina, PD Dr. med. (MD)

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Inclusion Criteria:

- Resectability, high-prominent and high risk uveal melanoma

Exclusion Criteria:

  • EOE
  • lux defect (If a medical report notes a "lux defect" alongside this, it refers to a deficit in light perception (from the Latin lux for light). It means the eye's ability to sense light, darkness, or light direction is impaired)

Descripción

Inclusion Criteria:

  • Functional Resectability,
  • Technical Resectability
  • high-prominent uveal melanoma

Exclusion Criteria:

  • EOE
  • At least in part remaining eye function that can be saved

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Local control
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Local control

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual acuity:
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual function assessed separately for each eye. Visual acuity:

decimal scale,range 2,0 - 0,01: decimal acuity scale

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Quality of Life, ophthalmic cancer-specific quality of life
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Quality of Life, ophthalmic cancer-specific quality of life

1) EORTC QLQ-OPT30 (ophthalmic cancer-specific quality of life): Scores range from 0-100; higher scores indicate greater visual impairment, ocular symptoms, and functional difficulties.

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Progression Free Survival
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Progression Free Survival

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Overall Survival
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Overall Survival

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual acuity:
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual function assessed separately for each eye. Visual acuity:

decimal scale,range 2,0 - 0,01: decimal acuity scale; furthermore, 1.Count-fingers, 2.hand-motion and 3.light-perception categories are recorded separately when acuity cannot be quantified: for each item: value yes / no

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual field
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual field: Automated perimetry, Visual Field Index (VFI, %): 0 % - 100%,

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Quality of Life general quality of life
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

EORTC QLQ-C30 (general quality of life): Scores range from 0-100; A) higher scores indicate better functioning/global quality of life B) symptom scores: indicate greater symptom burden on symptom scales.

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Retinal Nerve Fiber Layer
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Optical coherence tomography (OCT): Peripapillary retinal nerve fiber layer (RNFL) thickness, measured in µm and classified in percentiles (regarding normal values)

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Cornea
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

corneal outcome: thickness measured in µm

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Cornea
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Corneal outcome modified Stocker's classification:

category 0 No damage no injury category 1 corneal guttae without epithelial or stromal edema. category 2 corneal guttae with epithelial or stromal edema. category 3 corneal edema associated with scar formation. category 4 corneal opacification with neovascularization, modified Stocker's classification

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Corneal overall outcome classification
Periodo de tiempo: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

category 0 No corneal-ulcus category 1 Irregular punctate epithelial defects category 2 Non-healing epithelial defects / persistent epithelial defect (PED) category 3 Ulcer perforation

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de septiembre de 2019

Finalización primaria (Estimado)

30 de junio de 2027

Finalización del estudio (Estimado)

30 de junio de 2032

Fechas de registro del estudio

Enviado por primera vez

18 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

1 de noviembre de 2026

Publicado por primera vez (Actual)

3 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

dependent on the project

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir